| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Vedolizumab |
| Brand | Entyvio® |
| Indication | For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist. |
| Assessment Process | |
| Rapid review commissioned | 12/09/2014 |
| Rapid review completed | 01/10/2014 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 02/04/2015 |
| NCPE assessment completed | 13/11/2015 |
| NCPE assessment outcome | Reimbursement Not Recommended at the submitted price. |
The HSE has approved reimbursement following confidential price negotiations October 2017.
